JO3148B1 - مركب مثبط لإشارات مسار notch - Google Patents

مركب مثبط لإشارات مسار notch

Info

Publication number
JO3148B1
JO3148B1 JOP/2012/0190A JOP20120190A JO3148B1 JO 3148 B1 JO3148 B1 JO 3148B1 JO P20120190 A JOP20120190 A JO P20120190A JO 3148 B1 JO3148 B1 JO 3148B1
Authority
JO
Jordan
Prior art keywords
notch pathway
inhibitor compound
signaling inhibitor
pathway signaling
compound
Prior art date
Application number
JOP/2012/0190A
Other languages
English (en)
Inventor
Alan Stephenson Gregory
Arthur Hipskind Philip
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of JO3148B1 publication Critical patent/JO3148B1/ar

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)

Abstract

يوفر الاختراع الحالي مركب، أو ملح أو هيدرات مقبولين صيدليًا، وتركيبة صيدلية تحتوي على المركب المذكور، أو ملح أو هيدرات مقبولين صيدليًا، ويكون مفيدًا كمثبِّط لإشارات مسار Notch لعلاج السرطان.
JOP/2012/0190A 2011-07-27 2012-07-10 مركب مثبط لإشارات مسار notch JO3148B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161512016P 2011-07-27 2011-07-27
US201161560486P 2011-11-16 2011-11-16

Publications (1)

Publication Number Publication Date
JO3148B1 true JO3148B1 (ar) 2017-09-20

Family

ID=46598983

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2012/0190A JO3148B1 (ar) 2011-07-27 2012-07-10 مركب مثبط لإشارات مسار notch

Country Status (36)

Country Link
US (1) US8569286B2 (ar)
EP (1) EP2736920B1 (ar)
JP (1) JP6027110B2 (ar)
KR (1) KR101578309B1 (ar)
CN (1) CN103732612B (ar)
AP (1) AP4080A (ar)
AR (1) AR087107A1 (ar)
AU (1) AU2012287251B2 (ar)
BR (1) BR112014001600B1 (ar)
CA (1) CA2841178C (ar)
CL (1) CL2014000175A1 (ar)
CO (1) CO6862159A2 (ar)
CR (1) CR20140036A (ar)
CY (1) CY1116645T1 (ar)
DK (1) DK2736920T3 (ar)
DO (1) DOP2014000011A (ar)
EA (1) EA023044B1 (ar)
EC (1) ECSP14013179A (ar)
ES (1) ES2544937T3 (ar)
GT (1) GT201400012A (ar)
HR (1) HRP20150771T1 (ar)
HU (1) HUE027534T2 (ar)
IL (1) IL229988A (ar)
JO (1) JO3148B1 (ar)
MA (1) MA35611B1 (ar)
ME (1) ME02171B (ar)
MX (1) MX356536B (ar)
MY (1) MY184303A (ar)
PE (1) PE20141061A1 (ar)
PH (1) PH12014500215B1 (ar)
PL (1) PL2736920T3 (ar)
PT (1) PT2736920E (ar)
RS (1) RS54135B1 (ar)
SI (1) SI2736920T1 (ar)
TW (1) TWI568730B (ar)
WO (1) WO2013016081A1 (ar)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10350216B2 (en) 2013-01-14 2019-07-16 The Trustees Of Columbia University In The City Of New York Methods of treating, preventing and diagnosing leukemia and other blood diseases and disorders
CA2938626A1 (en) 2013-07-26 2015-01-29 John Rothman Compositions to improve the therapeutic benefit of bisantrene
TWI704151B (zh) 2014-12-22 2020-09-11 美商美國禮來大藥廠 Erk抑制劑
TWI609687B (zh) 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
JO3491B1 (ar) 2015-07-07 2020-07-05 Audion Therapeutics مركبات مثبطة لإشارات مسار notch
IL287136B2 (en) 2016-02-05 2023-09-01 Denali Therapeutics Inc Receptor inhibitors - interacting with protein kinase 1
CN120661674A (zh) 2016-03-15 2025-09-19 奥莱松基因组股份有限公司 用于治疗实体瘤的lsd1抑制剂的组合
AU2017249078B2 (en) * 2016-04-12 2022-10-20 Eli Lilly And Company Combination therapy with notch and CDK4/6 inhibitors for the treatment of cancer
MX380780B (es) * 2016-04-12 2025-03-12 Lilly Co Eli TERAPIA COMBINATORIA CON INHIBIDORES NOTCH Y PI3K/mTOR.
US10688104B2 (en) 2016-05-20 2020-06-23 Eli Lilly And Company Combination therapy with Notch and PD-1 or PD-L1 inhibitors
CN109562114A (zh) * 2016-08-31 2019-04-02 伊莱利利公司 用于治疗实体瘤的给药方案
CA3039405A1 (en) 2016-10-12 2018-04-19 Eli Lilly And Company Targeted treatment of mature t-cell lymphoma
HUE058802T2 (hu) 2016-12-09 2022-09-28 Denali Therapeutics Inc RIPK1 inhibitorokként alkalmas vegyületek
CN110461335A (zh) 2017-02-17 2019-11-15 弗雷德哈钦森癌症研究中心 用于治疗bcma相关癌症和自身免疫性失调的联合疗法
KR102845789B1 (ko) 2017-11-01 2025-08-14 주노 쎄러퓨티크스 인코퍼레이티드 B 세포 성숙 항원에 특이적인 키메라 항원 수용체 및 암호화 폴리뉴클레오타이드
US12193994B2 (en) * 2017-11-06 2025-01-14 Juno Therapeutics, Inc. Combination of a cell therapy and a gamma secretase inhibitor
AU2019266150A1 (en) * 2018-05-06 2021-01-07 Ayala Pharmaceuticals Inc. Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof
EP3860562A1 (en) 2018-10-02 2021-08-11 Frequency Therapeutics, Inc. Pharmaceutical compositions comprising otic therapeutic agents and related methods
SG11202111191YA (en) 2019-04-08 2021-11-29 Frequency Therapeutics Inc Combination of chir99021 and valproic acid for treating hearing loss
US11999750B2 (en) 2022-01-12 2024-06-04 Denali Therapeutics Inc. Crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-B][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP970705A2 (en) * 1996-12-23 1998-10-31 Warren J. Porter CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING "beta" -AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS
JP2002518481A (ja) 1998-06-22 2002-06-25 エラン ファーマシューティカルズ,インコーポレイテッド β−アミロイドペプチドの放出および/またはその合成を阻害するための化合物
CA2325389A1 (en) * 1998-06-22 1999-12-29 James E. Audia Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
HRP20050663A2 (en) 2003-02-04 2006-12-31 F. Hoffmann - La Roche Ag Malonamide derivatives as gamma-secretase inhibitors
AU2004270361B2 (en) 2003-09-09 2009-06-25 F. Hoffmann-La Roche Ag Malonamide derivatives blocking the activity of gama-secretase
WO2005040126A1 (en) 2003-10-06 2005-05-06 F. Hoffman-La Roche Ag Substituted dibenzo-azepine and benzo-diazepine derivatives useful as gamma-secretase inhibitors
KR101169628B1 (ko) 2006-03-27 2012-07-30 에프. 호프만-라 로슈 아게 감마 세크레테아제 저해제로서의 말론아미드 유도체
WO2008092786A1 (en) * 2007-02-02 2008-08-07 F. Hoffmann-La Roche Ag 6-oxo-6,7-dihydro-5h-dibenzo[b,d]azepin-7-yl derivatives
KR20100101624A (ko) 2008-01-11 2010-09-17 에프. 호프만-라 로슈 아게 암 치료를 위한 감마-세크레타제 저해제의 용도
WO2011060051A1 (en) * 2009-11-12 2011-05-19 University Of Massachusetts Methods for treating glioblastoma

Also Published As

Publication number Publication date
EP2736920B1 (en) 2015-07-01
HRP20150771T1 (hr) 2015-08-28
CN103732612A (zh) 2014-04-16
KR101578309B1 (ko) 2015-12-16
DOP2014000011A (es) 2014-07-31
BR112014001600B1 (pt) 2022-09-13
US8569286B2 (en) 2013-10-29
CN103732612B (zh) 2015-09-23
SI2736920T1 (sl) 2015-08-31
MX2014001084A (es) 2014-02-27
AP4080A (en) 2017-03-29
PE20141061A1 (es) 2014-09-06
AR087107A1 (es) 2014-02-12
WO2013016081A1 (en) 2013-01-31
ME02171B (me) 2015-10-20
MX356536B (es) 2018-06-01
PL2736920T3 (pl) 2015-11-30
ECSP14013179A (es) 2014-03-31
EA201490161A1 (ru) 2014-04-30
AP2014007362A0 (en) 2014-01-31
RS54135B1 (sr) 2015-12-31
AU2012287251A1 (en) 2014-01-30
CA2841178C (en) 2016-12-20
MY184303A (en) 2021-03-31
EP2736920A1 (en) 2014-06-04
CR20140036A (es) 2014-03-21
IL229988A (en) 2017-07-31
AU2012287251B2 (en) 2015-05-14
MA35611B1 (fr) 2014-11-01
JP2014527042A (ja) 2014-10-09
KR20140026624A (ko) 2014-03-05
JP6027110B2 (ja) 2016-11-16
HK1194086A1 (en) 2014-10-10
PH12014500215A1 (en) 2014-03-17
PH12014500215B1 (en) 2018-09-07
CA2841178A1 (en) 2013-01-31
NZ618891A (en) 2015-12-24
DK2736920T3 (en) 2015-07-20
CY1116645T1 (el) 2017-03-15
US20130029972A1 (en) 2013-01-31
GT201400012A (es) 2014-07-16
ES2544937T3 (es) 2015-09-07
TW201315732A (zh) 2013-04-16
PT2736920E (pt) 2015-09-16
TWI568730B (zh) 2017-02-01
CO6862159A2 (es) 2014-02-10
HUE027534T2 (en) 2016-11-28
CL2014000175A1 (es) 2014-08-22
BR112014001600A2 (pt) 2017-02-21
EA023044B1 (ru) 2016-04-29

Similar Documents

Publication Publication Date Title
JO3148B1 (ar) مركب مثبط لإشارات مسار notch
UA111382C2 (uk) Інгібітори протеїнкінази
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
IN2014DN10670A (ar)
EA201590224A1 (ru) Имидазотриазинкарбонитрилы, используемые в качестве ингибиторов киназы
PH12016500467A1 (en) Aminoheteroarlyl benzamides as kinase inhibitors
EA201391390A1 (ru) Циклопропиламины в качестве ингибиторов lsd
MX368703B (es) Un inhibidor de mdm2 derivado de acido benzoico para el tratamiento del cancer.
PH12015502031B1 (en) Tetrahydropyrrolothiazine compounds
EA201390085A1 (ru) Композиции ингибиторов киназ для лечения рака
AU2012214029A8 (en) Rorgammat inhibitors
MX2013011329A (es) Combinaciones de compuestos inhibidores de akt y erlotinib y metodos de uso.
MD4684B1 (ro) Formulări pe bază de imidazopirazine în calitate de inhibitori SYK
MX2013007336A (es) Compuestos de bi-heteroarilo como inhibidores de vps34.
MX2016006667A (es) Derivados de pirrolo-pirrolona y su uso como inhibidores.
EA201390499A1 (ru) Соединения, подходящие для ингибирования снк1
MX2015010619A (es) Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cancer.
MX362879B (es) Usos novedosos.
PH12014502492A1 (en) Pyrazole compounds as sglt1 inhibitors
JO3298B1 (ar) مشتقات جليكوبيرانوسيل-مستبدل و اندول-يوريا و استعمالاتهم كمثبطات sglt
UA110834C2 (uk) Сполука-інгібітор сигнального шляху notch
TN2013000515A1 (en) Notch pathway signaling inhibitor compound